Navigation Links
Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
Date:1/12/2012

SAN DIEGO, Jan. 12, 2012 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 1b study designed to evaluate the safety of MP4CO treatment in patients with sickle cell disease. MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis. This initial study will involve patients who are not currently undergoing a painful vaso-occlusive crisis. Preclinical studies show that carbon monoxide stabilizes the hemoglobin of patients with sickle cell disease and prevents the sickling of red blood cells.

"We are encouraged by the preclinical data on MP4CO and look forward to evaluating the safety and potential efficacy of this therapy in helping alleviate pain associated with a sickle cell crisis, while also potentially reducing the severity and duration of a crisis," said Dr. Jo Howard, at Guy's and St Thomas' Hospital, London, UK. "There is currently a dearth of treatments for painful vaso-occlusive crises associated with sickle cell disease, and MP4CO represents a potential treatment option for these patients."

The clinical trial is a multi-center, randomized, double-blind, controlled study that will enroll approximately 32 clinically stable adult patients with sickle cell disease who are not undergoing a painful vaso-occlusive crisis. The trial will be conducted at four sites across three countries, including the United Kingdom, France and Jamaica. The primary objective of the study is to establish the safety of treatment with MP4CO. The study will comprise ascending dose levels in five groups of single dose infusions followed by three groups of fractionated doses.

"This trial initiation is a key step towards providing a treatment to patie
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
2. Sangart Announces Closing of $50 Million Series G Financing
3. Sangart, Inc. Receives U.S. Orphan Drug Designation for use of MP4CO in Patients with Sickle Cell Disease
4. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
5. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
6. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
7. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
9. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Just days before the government of Sierra ... spread of Ebola, World Vision will begin a massive delivery ... private donations. McKesson, the largest healthcare services company ... affiliate McKesson Medical-Surgical donated four million pairs of latex gloves ... Sierra Leone,s needs for the next five months* ...
(Date:9/18/2014)... VIEW, Calif. and CHESTERBROOK, Pa. ... (Nasdaq: VVUS ) and Auxilium Pharmaceuticals, Inc. ... U.S. Food and Drug Administration (FDA) has approved a supplemental ... is now the only FDA-approved erectile dysfunction (ED) medication indicated ... sexual activity. STENDRA is a prescription medication in ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 ... Industry" and "2014 Market Research Report on Global ... its store. Photo - http://photos.prnewswire.com/prnh/20140917/146748 ... on Global Methyl Methacrylate (MMA) Industry" is a ... China and Global Methyl Methacrylate (MMA) ...
Breaking Medicine Technology:World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 2Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 3Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 4Methyl Methacrylate Market & Chinese Isothiocyanate Industry Trend Development 5
(Date:9/18/2014)... September 18, 2014 Relias Learning, the leader ... human services markets, today announced it has been named to ... private companies in America. , In the three-year period from ... up almost 2,000 spots on the Inc. 5000 list to ... , “The industries we serve continue to grow, and ...
(Date:9/18/2014)... PlatinumCode, a leading manufacturer and supplier ... the healthcare industry, announced earlier this month that ... their profits of the sale of eligible pink ... announcement, PlatinumCode has launched various marketing efforts to ... hospital labs with their popular “Pink Packs” of ...
(Date:9/18/2014)... “Awesome” is the way Emily W. describes her ... Internship Program at ARDX ( http://www.ardx.net ). Her ... as “Inspirational” and “Life-changing,” respectively. None of these ... be doing during their summer internship. Stacie was ... mindless tasks,” but, instead she was doing real, meaningful ...
(Date:9/18/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 (HealthDay ... stress disorder symptoms are almost three times more likely to ... The findings don,t prove a direct link between PTSD ... also possible that certain women are prone to food addiction ... research seems to add to existing evidence connecting PTSD to ...
(Date:9/18/2014)... 18, 2014 Fit Body Boot Camp ... fitness business in the country and its popularity, as both ... to grow enormously in 2014. , The company’s annual ... taking place in Costa Mesa, CA on September 26 and ... conferences yet. Founder Bedros Keuilian, who is also considered the ...
Breaking Medicine News(10 mins):Health News:Relias Learning Named to Inc. 5000 List for Second Consecutive Year 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4Health News:PTSD Link to Food Addiction Seen in Report 2Health News:PTSD Link to Food Addiction Seen in Report 3Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 2Health News:With Fit Body Boot Camp World Conference Nearing, Founder Explains the Fitness Boot Camp Franchise’s Success 3
... Sales increase 73% over Third Quarter 2007, EMERYVILLE, ... ) today reported its financial results,for the three and ... of $12.2 million, or $0.21 per diluted share, for ... $0.6 million, or $0.01 per diluted share,in the same ...
... 6 Pharmos Corporation,(Nasdaq: PARS ) today reported results ... a net loss of $2.8 million, or $0.11 per,share, for ... $3.5 million,or $0.14 per share, in the third quarter 2007. ... The decrease in net loss for the third quarter ...
... and service levels were key reasons, says union,president, ... Paul N. Urick, R.Ph., announced today that the ... its Participating Employers Health,and Welfare Fund have agreed ... members pharmacy coverage through FutureScripts. UFCW Local,1776,s new ...
... room doctors, study says , , THURSDAY, Nov. 6 (HealthDay ... at the hands of peers, immediate one-on-one mentoring on ... their risk of becoming victims again, a new study ... for assault injuries -- including gunshot, knife and fist-fight ...
... mostly young children -- infected, bringing total to 79, CDC ... cases of people becoming infected with salmonella traced to dry ... , The outbreak, which started in 2006, marks the first ... source of the bacterial infection in people. , As of ...
... Company Reports Seventeenth Consecutive Quarter Of Growth In ... Inc.,(Nasdaq: GXDX ), a specialized laboratory services ... third quarter of 2008, which includes a,$2.5 million ... prior,periods. This compares to revenues of $16.2 million ...
Cached Medicine News:Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 2Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 3Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 4Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 5Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 6Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 7Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 8Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 9Health News:Onyx Pharmaceuticals Reports Third Quarter and Nine-Month 2008 Financial Results 10Health News:Pharmos Corporation Reports 2008 Third Quarter Results 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 3Health News:Pharmos Corporation Reports 2008 Third Quarter Results 4Health News:Pharmos Corporation Reports 2008 Third Quarter Results 5Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 2Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 3Health News:FutureScripts(R) Wins Business of UFCW Local 1776 for Pharmacy Benefits 4Health News:Counseling Can Combat Youth Violence 2Health News:Salmonella Outbreak Tied to Dry Dog Food Continues 2Health News:Salmonella Outbreak Tied to Dry Dog Food Continues 3Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 2Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 3Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 4Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 5Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 6Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 7Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 8Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 9Health News:Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008 10
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: